Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Método DIVA para diferenciación de animales vacunados contra la brucelosis

Resumen

Tipo:
Oferta Tecnológica
Referencia:
13 ES 29FI 3SKU
Publicado:
01/06/2015
Caducidad:
31/05/2016
Resumen:
Un grupo de investigación de una universidad española ha desarrollado un nuevo método de etiquetado antigénico de vacunas de brucella lisa. Este método puede emplearse para diferenciar animales que han sido vacunados contra la brucelosis de animales que están infectados. El nuevo método y ensayo de diagnóstico basado en DIVA supera las limitaciones de las vacunas actuales contra la brucelosis. Se buscan socios interesados en establecer acuerdos de licencia, cooperación técnica, joint venture y financiación.

Details

Tittle:
Diva method for differentiation of animals vaccinated against brucellosis
Summary:
Researchers from a Spanish University have developed a new method for the antigenic tagging of brucellosis smooth vaccines. This method can be used to differentiate animals that have been vaccinated against brucellosis from those that are infected. This new vaccine tagging method and the appropriate diagnostic test based on the DIVA method will overcome the limitations of present brucellosis vaccines. License, technical cooperation, joint venture and finance agreements are offered.
Description:
Researchers from a Spanish University have developed a new method for the antigenic tagging of brucellosis smooth vaccines. Brucellosis is a disease of worldwide distribution affecting animals and human beings. Smooth live attenuated vaccines are the most efficient means for prevention and control of animal brucellosis. However, these vaccines carry a wild-type lipopolysaccharide that stimulates an antibody response not readily distinguished from that resulting from infection by wild-type brucellae. Since the most effective diagnostic tests detect antibodies to the lipopolysaccharide, vaccination severely compromises the specificity of diagnosis. This is considered the main drawback of current brucellosis vaccines and the main reason limiting their application.

The present invention describes a method for the antigenic tagging of brucellosis smooth vaccines that can be used to differentiate animals that have been vaccinated against brucellosis from those that are infected. The development includes the vaccine tagging method as well the associated diagnostic DIVA (differentiation of infected from vaccinated animals) test. The invention can be applied to Brucella abortus (cattle) and Brucella melitensis (sheep and goats) vaccines.

The researchers are looking for companies or research centres interested in license or joint venture agreements for the exploitation of this method, or technical cooperation / financial resources for the further development of this method and the production of a field trial.
Advantages and Innovations:
The development of this new tagging method makes possible the differentiation of Brucella infected from Brucella-vaccinated animals and it will overcome the limitations of present brucellosis vaccines.

The present invention includes both the vaccine tagging method and the associated DIVA test. Strains of Brucella are described that have been modified in the lipopolysaccharide O-antigen- to produce an immunogenic epitope that is different from those present in wild-type Brucella strains. The modified strains are transformed with bacterial acyltransferase (wbdR) and/or glycosyltransferase genes. Brucella vaccine strains expressing gene wbdR express lipopolysaccharide containing N-acetylperosamine, and this creates a new epitope that does not react with antibodies from Brucella abortus or Brucella melitensis infected animals. The modified lipopolysaccharide provides an immunological marker and the heterologous genes provide genetic markers that are absent in wild type strains.

This new tagging method for Brucellosis vaccines:

* Induces antibodies against the modified O-antigen and can be easily distinguished from wild-type Brucella strains.
*Can be applied to any classical or new developed smooth Brucella vaccine.
*Will allow sustained brucellosis vaccination, thus resulting in large economic benefits.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
PCT Applied

Partner sought

Type and Role of Partner Sought:
- Type of partner sought:
Companies, research centres.

- Specific area of activity of the partner:
Development of new brucellosis vaccines and diagnostic tools.

- Task to be performed by the partner sought:
Collaboration for the development of field tests.
Type of Partnership Considered:
Financial Resources
Joint Venture Agreement
Joint further development
License Agreement

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
07001 Agricultura
06001 Medicina, salud humana